文献速递角膜与眼表疾病

美国多中心临床试验:角膜胶原交联治疗屈光手术后角膜扩张

U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery.
PubMed 文献 · Ophthalmology · 2017-06-24

这项美国前瞻性随机多中心对照试验纳入179例屈光手术后角膜扩张受试者,比较标准角膜胶原交联(CXL)与仅用核黄素而不去除上皮的假对照组。治疗组最大K值1年较基线下降0.7D,对照组持续进展(组间差异1.3D,P<0.0001);治疗组CDVA平均提高5.0个logMAR字母,角膜混浊为最常见交联相关不良事件。结论认为CXL在改善最大K值、CDVA和UDVA方面有效且安全性良好。

要点

  • 治疗组最大K值1年较基线下降0.7D,对照组持续进展,组间差异1.3D(P<0.0001)。
  • 治疗组最大K值下降≥2.0D者14眼(18%),上升≥2.0D者3眼(4%)。
  • 治疗组CDVA平均提高5.0个logMAR字母,UDVA提高4.5个logMAR字母。

核心结论

  • 角膜胶原交联在治疗后1年有效改善角膜扩张眼的最大K值、CDVA和UDVA,且安全性良好。
  • CXL是首个获批用于减缓该角膜扩张过程进展的操作。

研究设计与样本

  • 前瞻性、随机、多中心、对照临床试验,纳入179例既往接受屈光手术后发生角膜扩张的受试者。
  • 治疗组接受标准CXL,假对照组仅接受核黄素且不去除上皮。

主要发现

  • 治疗组最大K值从基线至1年下降0.7D,对照组持续进展,治疗组与对照组之间差异为1.3D(P<0.0001)。
  • 治疗组最大K值下降≥2.0D者14眼(18%),上升≥2.0D者3眼(4%)。
  • 治疗组CDVA平均提高5.0个logMAR字母,23眼(32%)获得≥10个logMAR字母,3眼(4%)丢失≥10个logMAR字母。
  • 治疗组UDVA提高4.5个logMAR字母。
  • 角膜混浊是交联相关最常见的不良发现。

关键数值与推荐

  • 主要疗效标准为比较治疗组与对照组1年间地形图衍生的最大角膜曲率(K)变化。
  • 次要结局包括矫正远视力(CDVA)、未矫正远视力(UDVA)、显然验光球镜等效、内皮细胞计数和不良事件。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of corneal collagen crosslinking (CXL) for the treatment of corneal ectasia after laser refractive surgery. DESIGN: Prospective, randomized, multicenter, controlled clinical trial. PARTICIPANTS: One hundred seventy-nine subjects with corneal ectasia after previous refractive surgery. METHODS: The treatment group underwent standard CXL, and the sham control group received riboflavin alone without removal of the epithelium. MAIN OUTCOME MEASURES: The primary efficacy criterion was the change over 1 year of topography-derived maximum keratometry (K), comparing treatment with control groups. Secondary outcomes evaluated were corrected distance visual acuity (CDVA), uncorrected distance visual acuity (UDVA), manifest refraction spherical equivalent, endothelial cell count, and adverse events. RESULTS: In the crosslinking treatment group, the maximum K value decreased by 0.7 diopters (D) from baseline to 1 year, whereas there was continued progression in the control group (1.3 D difference between treatment and control, P < 0.0001). In the treatment group, the maximum K value decreased by 2.0 D or more in 14 eyes (18%) and increased by 2.0 D or more in 3 eyes (4%). The CDVA improved by an average of 5.0 logarithm of the minimum angle of resolution (logMAR) letters. Twenty-three eyes (32%) gained and 3 eyes (4%) lost 10 or more logMAR letters. The UDVA improved 4.5 logMAR letters. Corneal haze was the most frequently reported crosslinking-related adverse finding. CONCLUSIONS: Corneal collagen crosslinking was effective in improving the maximum K value, CDVA, and UDVA in eyes with corneal ectasia 1 year after treatment, with an excellent safety profile. CXL is the first approved procedure to diminish progression of this ectatic corneal process.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Hersh PS, Stulting RD, Muller D, et al. U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery. Ophthalmology. 2017. PMID: 28655538. doi:10.1016/j.ophtha.2017.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。